Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Withdrawn 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Sarcoma 1Gynecologic 1Gastrointestinal 1Breast 1

Conditions

Pancreatic Neoplasms 2Sarcoma 1Ovarian Neoplasms 1Colorectal Neoplasms 1Colonic Neoplasms 1Carcinoma, Hepatocellular 1Breast Neoplasms 1

Interventions

pembrolizumab 50Cyclophosphamide 25Carboplatin 25Gemcitabine 20Cisplatin 19fludarabine 18Nivolumab 17Paclitaxel 16Bevacizumab 15Specimen Handling 14Fluorouracil 11Magnetic Resonance Spectroscopy 10aldesleukin 9Oxaliplatin 9Irinotecan 9Docetaxel 9Biopsy 9olaparib 8Trastuzumab 8durvalumab 7atezolizumab 7Hyperthermic Intraperitoneal Chemotherapy 7Albumin-Bound Paclitaxel 7Taxes 6Leucovorin 6Ipilimumab 6Interleukin-2 6Cetuximab 6Capecitabine 6130-nm albumin-bound paclitaxel 6

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Ovarian Neoplasms × pidilizumab × Gastrointestinal × Clear all
NCT01386502 2017-07-02

CT-011 and p53 Genetic Vaccine for Advanced Solid Tumors

National Institutes of Health Clinical Center (CC)

Phase 1 Withdrawn
BreastGastrointestinalGynecologicSarcoma

Breast Neoplasms, Colonic Neoplasms, Ovarian Neoplasms, Pancreatic Neoplasms, Sarcoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡